Wave Life Sciences Ltd.
NASDAQ:WVEBiotechnology
+$0.10 today
- Market cap
- $546.32M
- Beta
- -1.33
- P/E (TTM)
- -6.6
- EPS (TTM)
- -$0.92
Volume 2.21M
Average 4.86M
WVE Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Wave Life Sciences Ltd.NASDAQ: WVE
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue growth accelerates
Q1 FY2026 revenue of $38.25M rose 316.9% year over year, ahead of the -31.6% change in trailing-twelve-month revenue. Sequentially, it rose 121.8% from the prior quarter. Over 3 fiscal years it compounded at +127.1% a year.
Context
- Revenue increased in 1 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 15 analysts of $63.63M (+48.9%) for the fiscal year ending Dec 2026, a step up from the -60.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $38.25M+121.8% QoQ
- Last fiscal yearDec 2025
- $42.73M-60.5% YoY
- LTMMar 2026
- $71.8M-31.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +316.9% | -14.4% | -331.2 pp |
| 1 year | -60.5% | +48.9% | +109.5 pp |
| 3-year CAGR | +127.1% | +7.4% | -119.7 pp |
| 5-year CAGR | +53.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 42.73M USD
- Year-over-year change
- -60.5%
- 4-year CAGR
- +1.1%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 42.73M | -60.5% |
| FY2024 | 2024-12-31 | 108.3M | -4.4% |
| FY2023 | 2023-12-31 | 113.31M | +3005.1% |
| FY2022 | 2022-12-31 | 3.65M | -91.1% |
| FY2021 | 2021-12-31 | 40.96M | — |
Revenue vs competitors
How WVE compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of -31.6% is the 6th highest of 9, against a peer median of -15.7%.
- Over three fiscal years its annual growth of +127.1% compares with a peer median of +23.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $4.8B USD | +95.1% | +53.0% | |
| LTM Mar 2026 | $2.18B USD | -2.2% | +33.1% | |
| LTM Sep 2026 | $959.76M USD | -0.7% | +17.1% | |
| LTM Sep 2026 | $450.82M USD | -45.6% | +23.3% | |
| LTM Mar 2026 | $71.8M USD | -31.6% | +127.1% | |
| LTM Mar 2026 | $66.09M USD | +45.0% | +9.1% | |
| LTM Mar 2026 | $45.35M USD | -66.4% | -31.1% | |
| LTM Mar 2026 | $32.08M USD | -83.2% | +145.9% | |
| LTM Mar 2026 | €13.44M EUR | -29.2% | +62.0% | |
| LTM Mar 2026 | $921.49K USD | — | -68.4% | |
| LTM Mar 2026 | $0 USD | — | — | |
| Peer median (excluding WVE) | — | -15.7% | +23.3% | |
Competitors are the stored peer set for WVE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 40.96M | 3.65M | 113.31M | 108.3M | 42.73M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 8.85M |
| Gross Profit | 40.96M | 3.65M | 113.31M | 108.3M | 33.88M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 79.3% |
| Research & Development | 121.88M | 115.86M | 130.01M | 159.68M | 182.78M |
| Selling, General & Admin | 46.11M | 50.51M | 51.29M | 59.02M | 75.33M |
| Operating Expenses | 167.98M | 166.37M | 181.3M | 218.71M | 249.26M |
| Depreciation & Amortization | 9.84M | 10.11M | 9.21M | 8.66M | 8.85M |
| EBITDA | (112.61M) | (151.03M) | (48.98M) | (88.35M) | (195.53M) |
| EBITDA Margin | -274.9% | -4138.9% | -43.2% | -81.6% | -457.6% |
| Operating Income | (127.02M) | (162.72M) | (68M) | (110.4M) | (215.38M) |
| Operating Margin | -310.1% | -4459.3% | -60.0% | -101.9% | -504.1% |
| Interest Income | 30K | 0 | 0 | 0 | 10.48M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4.57M | 1.58M | 9.81M | 13.4M | 11.01M |
| Income Before Tax | (122.45M) | (161.14M) | (58.19M) | (97.01M) | (204.38M) |
| Pre-Tax Margin | -298.9% | -4416.1% | -51.4% | -89.6% | -478.3% |
| Income Tax Expense | (204K) | 681K | (677K) | 0 | 0 |
| Net Income | (122.25M) | (161.82M) | (57.51M) | (97.01M) | (204.38M) |
| Net Margin | -298.4% | -4434.7% | -50.8% | -89.6% | -478.3% |
| EPS (Basic) | (2.36) | (2.05) | (0.54) | (0.70) | (1.21) |
| EPS (Diluted) | (2.36) | (2.05) | (0.54) | (0.70) | (1.21) |
| Weighted Avg Shares | 51.83M | 78.86M | 106.1M | 138.28M | 168.65M |
| Weighted Avg Shares (Diluted) | 51.83M | 78.86M | 106.1M | 138.28M | 168.65M |
Wave Life Sciences Ltd.
NASDAQ:WVE
Intrinsic Alpha fair value
Locked
Current Price
$2.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.